why choose us

First received: June 07, 2023

Clinical Trial: Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)

Study Status: Completed

Recruit Status: RECRUITING

Condition: HR Positive/HER2 Low Expression Metastatic Breast Cancer

Study Type: INTERVENTIONAL


Official Title: Disitamab Vedotin or Endocrine Therapy for Patients With Metastatic Breast Cancer With Hormone Receptor-positive and HER2-low-expression

Brief Summary: Hormone receptor positive, HER2-low expression metastatic breast cancer is the main type of breast cancer, accounting for about 50% - 60%.However, this type of patients lack ideal therapeutic drugs after the failure of first-line standard endocrine therapy, and the median overall survival time is only 30 months.Therefore, finding more efficient and safe therapeutic drugs for these patients has become a big clinical challenge at present.Disitamab Vedotin (DV), as a new class I Antibody-Drug Conjugates drug, can…

Read more